Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 10560679.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.
Medical subject headings
- Contraceptives, Oral, Synthetic
- Progesterone Congeners
- Thromboembolism